

# Catherine Van Poznak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9610848/publications.pdf>

Version: 2024-02-01

31  
papers

2,292  
citations

430754

18  
h-index

477173

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

3916  
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. <i>Oral Diseases</i> , 2022, 28, 193-201.	1.5	7
2	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 787-800.	0.8	44
3	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8
4	Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies. <i>Current Osteoporosis Reports</i> , 2021, 19, 452-461.	1.5	0
5	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
6	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	3.2	91
7	De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 507-517.	1.1	23
8	Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3784-3792.	3.2	41
9	Weight loss and bone mineral density in obese adults: a longitudinal analysis of the influence of very low energy diets. <i>Clinical Diabetes and Endocrinology</i> , 2018, 4, 14.	1.3	7
10	Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone. <i>JAMA Oncology</i> , 2017, 3, 906.	3.4	134
11	Reply to T.J. Powles et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2720-2721.	0.8	0
12	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology Cancer Care Ontario Focused Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3978-3986.	0.8	127
13	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2838-2847.	0.8	241
14	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology Cancer Care Ontario Focused Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 822-824.	2.5	9
15	Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 116-122.	1.8	3
16	Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls. <i>Journal of Bone Reports &amp; Recommendations</i> , 2016, 2, .	0.0	2
17	TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. <i>Clinical Cancer Research</i> , 2016, 22, 5706-5712.	3.2	30
18	Periodontal health in breast cancer patients on aromatase inhibitors versus postmenopausal controls: a longitudinal analysis. <i>Journal of Clinical Periodontology</i> , 2016, 43, 659-667.	2.3	12

#	ARTICLE	IF	CITATIONS
19	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 1134-1150.	0.8	683
20	Utility of patient-derived lymphoblastoid cell lines as an <i>ex vivo</i> capecitabine sensitivity prediction model for breast cancer patients. <i>Oncotarget</i> , 2016, 7, 38359-38366.	0.8	4
21	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Oncology Practice</i> , 2015, 11, 514-516.	2.5	26
22	Periodontal Health in Women With Early-Stage Postmenopausal Breast Cancer Newly on Aromatase Inhibitors: A Pilot Study. <i>Journal of Periodontology</i> , 2015, 86, 906-916.	1.7	20
23	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 2695-2704.	0.8	279
24	Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 163-172.	1.1	23
25	ACR Appropriateness Criteria <sup>®</sup> Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis. <i>Journal of Palliative Medicine</i> , 2015, 18, 573-584.	0.6	40
26	Hypocalcaemia in patients with metastatic bone disease treated with denosumab. <i>European Journal of Cancer</i> , 2015, 51, 1812-1821.	1.3	106
27	Oncotype Dx Results in Multiple Primary Breast Cancers. <i>Breast Cancer: Basic and Clinical Research</i> , 2014, 8, BCBCR.S13727.	0.6	17
28	Lipid profiles within the SABRE trial of anastrozole with and without risedronate. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1141-1147.	1.1	8
29	Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 967-975.	0.8	202
30	Hypercalcemia of Malignancy Remains a Clinically Relevant Problem. <i>Cancer Journal (Sudbury, Mass)</i> , 2006, 12, 21-23.	1.0	2
31	Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. <i>Oncology</i> , 2006, 20, 1053-62; discussion 1065-6.	0.4	26